Combining immunotherapy with irreversible electroporation for advanced pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II study evaluates the effectiveness and safety of using irreversible electroporation in conjunction with the immunotherapy drug Nivolumab for patients with locally advanced pancreatic adenocarcinoma. Patients will undergo irreversible electroporation followed by treatment with Nivolumab to assess the combined impact on tumor response. The study aims to determine if this combination can improve outcomes compared to standard treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years if age
* Diagnosed with stage III pancreatic cancer
* Tumor is measurable
* Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2)
* Willing and able to comply with the protocol requirements
* Able to comprehend and have signed the informed consent to participate

Exclusion Criteria:

* Participating in another clinical trial for the treatment of cancer at time of screening
* Are pregnant or currently breast feeding
* Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
* Have non-removable implants with metal parts within 1 cm of the target lesion
* Had a myocardial infarction within 3 months prior to enrollment

Where it's running

• University of Louisville
  Louisville, Kentucky, United States Recruiting

Study contacts

• Principal investigator: Robert Martin, MD, PhD — University of Louisville
• Study coordinator: Robert Martin, MD, PhD
• Email: robert.martin@louisville.edu
• Phone: 502-629-3355

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• MyCap app to track time burden of pancreatic cancer treatment

  This study tests whether a mobile app can help adults with pancreatic cancer log the time they spend on cancer care.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07619391

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

• Lorigerlimab in pancreatic cancer with BRCA/RAD51 gene mutations

  This phase 2 study tests Lorigerlimab in adults with metastatic pancreatic cancer who have BRCA1/2, PALB2, RAD51C, or RAD51D germline mutations.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07565155

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.